Peter Merkel

Summary

Affiliation: Boston University
Country: USA

Publications

  1. ncbi request reprint Comparison between the standard anticardiolipin antibody test and a new phospholipid test in patients with connective tissue diseases
    P A Merkel
    Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    J Rheumatol 26:591-6. 1999
  2. ncbi request reprint Part 1: The need for novel treatment regimens for ANCA-associated vasculitis
    P A Merkel
    Boston University School of Medicine, Boston, MA 02118, USA
    Clin Exp Rheumatol 25:S72-3. 2007
  3. doi request reprint Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial
    Peter A Merkel
    Boston University School of Medicine, Boston, MA 02118, USA
    Arthritis Rheum 59:699-705. 2008
  4. pmc The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis
    Peter A Merkel
    Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, USA
    J Rheumatol 38:1480-6. 2011
  5. pmc Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis
    P A Merkel
    Vasculitis Center, E5, Boston University School of Medicine, 72 East Concord Street, Boston, Massachussets, 02118, USA
    Ann Rheum Dis 68:103-6. 2009
  6. pmc Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9
    Peter A Merkel
    Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA 02118, USA
    J Rheumatol 36:2362-8. 2009
  7. ncbi request reprint Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7
    Peter A Merkel
    Boston University School of Medicine, Boston, MA 02118, USA
    J Rheumatol 32:2488-95. 2005
  8. ncbi request reprint Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6
    Peter A Merkel
    Arthritis Center, Section of Rheumatology, Boston University School of Medicine, Boston, MA 02118, USA
    J Rheumatol 30:1630-47. 2003
  9. ncbi request reprint Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study
    Peter A Merkel
    Boston University School of Medicine, Vasculitis Center, E 5, 715 Albany Street, Boston, MA 02118, USA
    Ann Intern Med 142:620-6. 2005
  10. ncbi request reprint Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon
    Peter A Merkel
    Harvard Medical School, Boston, Massachusetts, USA
    Arthritis Rheum 46:2410-20. 2002

Detail Information

Publications47

  1. ncbi request reprint Comparison between the standard anticardiolipin antibody test and a new phospholipid test in patients with connective tissue diseases
    P A Merkel
    Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    J Rheumatol 26:591-6. 1999
    ..We evaluated the diagnostic utility of a new aPL antibody test kit with a unique phospholipid mixture designed to be more specific than the standard anticardiolipin ELISA...
  2. ncbi request reprint Part 1: The need for novel treatment regimens for ANCA-associated vasculitis
    P A Merkel
    Boston University School of Medicine, Boston, MA 02118, USA
    Clin Exp Rheumatol 25:S72-3. 2007
  3. doi request reprint Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial
    Peter A Merkel
    Boston University School of Medicine, Boston, MA 02118, USA
    Arthritis Rheum 59:699-705. 2008
    ..To determine the validity, reliability, and feasibility of durometer measurements of skin hardness as an outcome measure in clinical trials of scleroderma...
  4. pmc The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis
    Peter A Merkel
    Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, USA
    J Rheumatol 38:1480-6. 2011
    ..This report reviews the domains of illness in AAV included in the OMERACT core set, describes the instruments validated to measure these domains, and presents the approved core set...
  5. pmc Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis
    P A Merkel
    Vasculitis Center, E5, Boston University School of Medicine, 72 East Concord Street, Boston, Massachussets, 02118, USA
    Ann Rheum Dis 68:103-6. 2009
    ..An exercise comparing six different vasculitis instruments was performed...
  6. pmc Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9
    Peter A Merkel
    Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA 02118, USA
    J Rheumatol 36:2362-8. 2009
    ..This process has been informed by several ongoing projects providing data on outcomes of disease activity, disease-related damage, multidimensional health-related quality of life, and patient-reported ratings of the burden of vasculitis...
  7. ncbi request reprint Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7
    Peter A Merkel
    Boston University School of Medicine, Boston, MA 02118, USA
    J Rheumatol 32:2488-95. 2005
    ....
  8. ncbi request reprint Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6
    Peter A Merkel
    Arthritis Center, Section of Rheumatology, Boston University School of Medicine, Boston, MA 02118, USA
    J Rheumatol 30:1630-47. 2003
    ..The current level of validation of outcome measures in SSc is assessed according to the guidelines set forth by prior OMERACT meetings...
  9. ncbi request reprint Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study
    Peter A Merkel
    Boston University School of Medicine, Vasculitis Center, E 5, 715 Albany Street, Boston, MA 02118, USA
    Ann Intern Med 142:620-6. 2005
    ..Venous thrombotic events (VTEs) have been observed in Wegener granulomatosis, but the incidence rate is not known...
  10. ncbi request reprint Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon
    Peter A Merkel
    Harvard Medical School, Boston, Massachusetts, USA
    Arthritis Rheum 46:2410-20. 2002
    ....
  11. ncbi request reprint Evaluation and treatment of vasculitis in the critically ill patient
    Peter A Merkel
    Rheumatology Section, Boston Medical Center, Arthritis Center, Boston University School of Medicine, 730 Albany Street, Boston, MA 02118, USA
    Crit Care Clin 18:321-44. 2002
    ..Rapid initiation of immunosuppressive therapy for critically ill patients with vasculitis is crucial and may be life-saving...
  12. ncbi request reprint Drug-induced vasculitis
    P A Merkel
    Arthritis Center, Boston University School of Medicine, and Rheumatology Section, Boston University Medical Center, Boston, Massachusetts, USA
    Rheum Dis Clin North Am 27:849-62. 2001
    ..Increasing understanding of the pathophysiologic characteristics of all inflammatory vasculitides should lead to better diagnostic and therapeutic approaches to DIV...
  13. pmc Rituximab versus cyclophosphamide for ANCA-associated vasculitis
    John H Stone
    Massachusetts General Hospital, Boston, USA
    N Engl J Med 363:221-32. 2010
    ..Uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-based regimen...
  14. pmc B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis
    Robert Lafyatis
    Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Arthritis Rheum 60:578-83. 2009
    ....
  15. doi request reprint Genetics of vasculitis
    Paul A Monach
    Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Curr Opin Rheumatol 22:157-63. 2010
    ..Cohorts have been assembled that are of sufficient size to allow application of up-to-date methods of genetic analysis. This review will summarize the current understanding of the genetics of several forms of vasculitis...
  16. ncbi request reprint Durometry for the assessment of skin disease in systemic sclerosis
    Eugene Y Kissin
    Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Arthritis Rheum 55:603-9. 2006
    ..To examine the validity of a durometer to objectively measure skin hardness in systemic sclerosis (SSc), and to compare digital durometry with the modified Rodnan skin score (MRSS) and ultrasonography...
  17. ncbi request reprint Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial
    Dinesh Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, Los Angeles, California, USA
    J Rheumatol 32:832-40. 2005
    ....
  18. pmc Thromboembolic disease in vasculitis
    Gunnar Tomasson
    The Vasculitis Center, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts 02118, USA
    Curr Opin Rheumatol 21:41-6. 2009
    ..To give an overview of recent clinical findings of thromboembolic disease in vasculitis and provide insight into possible explanations of the association between thrombosis and inflammation...
  19. ncbi request reprint Development of a provisional core set of response measures for clinical trials of systemic sclerosis
    D Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, California 90095, USA
    Ann Rheum Dis 67:703-9. 2008
    ..To develop a provisional core set of response measures for clinical trials of systemic sclerosis (SSc)...
  20. ncbi request reprint The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event
    Jodi K Sebastian
    Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Rheumatol 34:2446-50. 2007
    ..The frequency of anticardiolipin antibodies (aCL), anti-beta2-glycoprotein antibodies (anti-beta2-GP), and several genetic hypercoagulable factors were examined in a large cohort of patients with WG...
  21. doi request reprint Case records of the Massachusetts General Hospital. Case 31-2008. A 39-year-old man with chest pain, arthralgias, and a mediastinal mass
    Peter A Merkel
    Arthritis Center, Boston Medical Center, and the Department of Medicine, Boston University School of Medicine, Boston, USA
    N Engl J Med 359:1603-14. 2008
  22. ncbi request reprint Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations
    Jodi K Sebastian
    Boston University, Boston, Massachusetts 02118, USA
    J Rheumatol 34:1027-31. 2007
    ..We examined a large, well-characterized cohort of patients with WG and active disease for the presence of AECA...
  23. ncbi request reprint Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis
    Eugene Y Kissin
    Boston University Medical Center, Boston, Massachusetts, USA
    Arthritis Rheum 54:3655-60. 2006
    ..To investigate the correlation between the degree of dermal fibrosis and myofibroblast infiltration using clinical assessments of skin thickness and hardness in systemic sclerosis (SSc)...
  24. pmc Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda
    Haner Direskeneli
    Marmara University School of Medicine, Istanbul, Turkey
    J Rheumatol 38:1471-9. 2011
    ....
  25. pmc Nutrient status of adults with cystic fibrosis
    Catherine M Gordon
    Division of Endocrinology, Children s Hospital Boston, Boston, MA 22015, USA
    J Am Diet Assoc 107:2114-9. 2007
    ..These findings call into question the applicability of established nutrient thresholds for patients with cystic fibrosis...
  26. ncbi request reprint Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis
    Alfred D Mahr
    Vasculitis Center, Boston University School of Medicine, 75 Albany Street, Boston, MA 02118, USA
    Arthritis Rheum 56:2789-97. 2007
    ..To reevaluate the efficacy and safety of adjunctive low-dose methotrexate (MTX) in giant cell arteritis (GCA)...
  27. pmc Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis
    Alfred D Mahr
    Boston University, Boston, Massachusetts 02118, USA
    Arthritis Rheum 59:884-91. 2008
    ..To assess the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) with respect to its selection and weighting of items...
  28. ncbi request reprint A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis
    Gary S Hoffman
    Cleveland Clinic Foundation, Cleveland, Ohio 44915, USA
    Arthritis Rheum 46:1309-18. 2002
    ....
  29. doi request reprint A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase di
    Arnold E Postlethwaite
    University of Tennessee, Memphis, and VAMC, Memphis
    Arthritis Rheum 58:1810-22. 2008
    ..To investigate the safety and efficacy of oral bovine type I collagen (CI) treatment in patients who have had diffuse cutaneous systemic sclerosis (dcSSc; scleroderma) for <or=10 years...
  30. ncbi request reprint Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis
    Javier D Finkielman
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 147:611-9. 2007
    ..The utility of antineutrophil cytoplasmic antibody (ANCA) levels to guide the management of patients with Wegener granulomatosis remains controversial...
  31. ncbi request reprint Outcome measurements in scleroderma: results from a delphi exercise
    Hashim Gazi
    Division of Rheumatology, Department of Medicine, The University of Western Ontario, London, Ontario, Canada
    J Rheumatol 34:501-9. 2007
    ..To obtain a consensus on the minimal clinically relevant treatment effect in various scleroderma disease outcome measures to be used in future clinical trials...
  32. ncbi request reprint Scleroderma--developing measures of response
    Daniel E Furst
    University of California at Los Angeles, CA 90025, USA
    J Rheumatol 32:2477-80. 2005
    ..Deliberations focused on progress in the assessment of gastrointestinal disease, renal physiology, vascular damage, and the unique challenges inherent in studying pediatric patients with scleroderma...
  33. ncbi request reprint Outcome measures in systemic sclerosis: an update on instruments and current research
    Dinesh Khanna
    Division of Immunology, Department of Internal Medicine, University of Cincinnati, PO Box 670563, Cincinnati, OH 45267 0563, USA
    Curr Rheumatol Rep 9:151-7. 2007
    ..This review provides an update on currently used outcome measures in SSc with specific attention on newer tools and also describes methodology under development...
  34. pmc EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis
    Bernhard Hellmich
    Department of Rheumatology, University Hospital of Schleswig Holstein, Campus Lubeck, Lubeck, Germany
    Ann Rheum Dis 66:605-17. 2007
    ..To develop the European League Against Rheumatism (EULAR) recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis...
  35. ncbi request reprint Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial
    Gary S Hoffman
    Center for Vasculitis Care and Research, The Cleveland Clinic Foundation, Lerner College of Medicine, Cleveland, Ohio 44195, USA
    Ann Intern Med 146:621-30. 2007
    ..Tumor necrosis factor-alpha is present in arteries in giant cell arteritis...
  36. ncbi request reprint Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192
    Christopher P Denton
    Royal Free Hospital, London, UK
    Arthritis Rheum 56:323-33. 2007
    ..To evaluate CAT-192, a recombinant human antibody that neutralizes transforming growth factor beta1 (TGFbeta1), in the treatment of early-stage diffuse cutaneous systemic sclerosis (dcSSc)...
  37. ncbi request reprint Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)
    Philip Seo
    Johns Hopkins University, Baltimore, Maryland
    Arthritis Rheum 52:2168-78. 2005
    ..To analyze damage occurring in patients with Wegener's granulomatosis (WG) enrolled in the WG Etanercept Trial (WGET) and to correlate that damage with disease activity, adverse events, and quality of life...
  38. ncbi request reprint Hearing loss in Wegener's granulomatosis
    Sivasanker Bakthavachalam
    Department of Otolaryngology Head and Neck Surgery, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Otol Neurotol 25:833-7. 2004
    ..STUDY DESIGN, SETTING, AND PATIENTS: Retrospective cohort review of all patients with Wegener's granulomatosis seen in 1 year at an academic medical center...
  39. ncbi request reprint Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis
    Gary S Hoffman
    Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Arthritis Rheum 50:2296-304. 2004
    ..In this study, we assessed therapy with anti-TNF agents in patients with TA that was not controlled by glucocorticoid therapy or other immunosuppressants...
  40. ncbi request reprint Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial
    John H Stone
    Johns Hopkins University, Baltimore, Maryland, USA
    Arthritis Rheum 54:1608-18. 2006
    ..This study was undertaken to further explore the potential association between anti-TNF therapy and the development of malignancy in these patients...
  41. ncbi request reprint ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis
    Javier D Finkielman
    Thoracic Disease Research Unit, Division of Pulmonary and Critical Care Medicine, Mayo Clinic and Foundation, Rochester, Minn 55905, USA
    Am J Med 120:643.e9-14. 2007
    ..The objective of this study was to determine the frequency of ANCA in patients with active Wegener's granulomatosis and to assess the influence of disease severity on test results...
  42. ncbi request reprint A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis
    John H Stone
    The Johns Hopkins Vasculitis Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Arthritis Rheum 52:902-10. 2005
    ..To identify serum ion patterns that distinguish remission from active disease in patients with Wegener's granulomatosis (WG)...
  43. ncbi request reprint Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multiorgan dysfunction
    Dimitrios Vassilopoulos
    The Henry Dunant Hospital, Athens, Greece
    Arthritis Rheum 49:151-5. 2003
    ..To determine the prevalence of antineutrophil cytoplasmic antibodies (ANCA) in patients with diseases that may mimic systemic vasculitides, such as severe multiorgan dysfunction (MOD) and parenchymal pulmonary disorders...
  44. doi request reprint Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis
    Oliver Distler
    University Hospital Zurich, Zurich, Switzerland
    Arthritis Rheum 59:867-75. 2008
    ..The aim of the present study was to establish an expert consensus regarding which outcome measures are most appropriate for clinical trials in PAH-SSc...
  45. doi request reprint Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I
    Charles G Helmick
    CDC, Atlanta, Georgia 30341 3717, USA
    Arthritis Rheum 58:15-25. 2008
    ..A companion article (part II) addresses additional conditions...
  46. ncbi request reprint The future of damage assessment in vasculitis
    Philip Seo
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Rheumatol 34:1357-71. 2007
    ..This initiative is part of a larger international effort to create a unified approach to disease assessment for the primary systemic vasculitides...
  47. ncbi request reprint Herpes zoster in immunocompromised patients: incidence, timing, and risk factors
    Peter K Wung
    Johns Hopkins University School of Medicine, Johns Hopkins University, Baltimore, MD, USA
    Am J Med 118:1416. 2005
    ..To evaluate the risk factors for herpes zoster as well as the incidence and timing of this complication in patients who were treated with immunosuppression because of active Wegener's granulomatosis...

Research Grants12

  1. Plasma Exchange and Glucocorticoids for Treatment of ANCA-Associated Vasculitis
    Peter Merkel; Fiscal Year: 2009
    ..This application seeks funding to support 5 study sties in the United States and combine resources with funding from the United Kingdom. ..
  2. Vasculitis Outcome Measures: Development and Validation
    Peter Merkel; Fiscal Year: 2006
    ..I.s, Drs. John Stone and Peter Merkel. There are two Specific Aims: Aim 1: To develop and validate a consensus disease activity measure for ANCA-..
  3. Clinical Research for Rare Diseases: Opportunities, Challenges, and Solutions
    Peter Merkel; Fiscal Year: 2007
    ..Finally, the proceedings will be posted on the web and a summary article will be published. If this conference proves successful, we plan on having similar sessions attached to future RDCRC meetings. ..
  4. Vasculitis Clinical Research Network (VCRN)
    Peter Merkel; Fiscal Year: 2006
    ..AIM 5. Build and contribute to an electronic website resource with substantive content for clinicians, researchers, and patients. ..
  5. Studies in Scleroderma and Cystic Fibrosis Osteoporosis
    Peter Merkel; Fiscal Year: 2005
    ..A unique seminar and a series of support services at the host institution will further complement the training program. ..
  6. Plasma Exchange and Glucocorticoids for Treatment of ANCA-Associated Vasculitis
    Peter A Merkel; Fiscal Year: 2010
    ..This application seeks funding to support 5 study sties in the United States and combine resources with funding from the United Kingdom. ..